New data on MIV-818 will be presented at EASL's International Liver Congress™ 2017
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today informs that preclinical data on MIV-818 will be presented by Medivir at The International Liver Congress™ 2017 of the European Association for the Study of the Liver (EASL) in Amsterdam, on 19-23 April. The poster presentation, abstract SAT-123, is entitled “Liver-targeting with the novel nucleotide prodrug MIV-818 designed for the treatment of liver cancers” and will include data on the anticancer activity and pharmacokinetic profile of MIV-818. Details of all presentations for The International Liver Congress™ 2017 are